Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$73.47 USD

73.47
800,946

-1.13 (-1.52%)

Updated May 20, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 248)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.

    Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?

    by Zacks Equity Research

    Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.

      Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

      by Zacks Equity Research

      Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

        Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

        by Zacks Equity Research

        Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

          Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

          by Zacks Equity Research

          ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

            Henry Schein (HSIC) Buys ABASE, Expands in Animal Health

            by Zacks Equity Research

            Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.

              Patterson Companies' (PDCO) Dental Segment Shows Weakness

              by Zacks Equity Research

              Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).

                Henry Schein Buys eVetPractice, Boosts Technology & VAS Arm

                by Zacks Equity Research

                Henry Schein (HSIC) adopts initiatives to strengthen hold in the high-potential healthcare IT market.

                  Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind

                  by Zacks Equity Research

                  Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.

                    Implied Volatility Surging for Henry Schein (HSIC) Stock Options

                    by Zacks Equity Research

                    Investors need to pay close attention to Henry Schein (HSIC) stock based on the movements in the options market lately.

                      Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

                      by Zacks Equity Research

                      Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.

                        Henry Schein (HSIC) Misses Q3 Earnings, Revenues Beat Estimate

                        by Zacks Equity Research

                        Henry Schein (HSIC) gains from strength in all the business segments in Q3.

                          Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?

                          by Zacks Equity Research

                          In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.

                            4 Medical Device Stocks to Top Q3 Earnings

                            by Zacks Equity Research

                            A look at how medical device players are poised for this earnings season.

                              Key Factors to Influence PerkinElmer's (PKI) Q3 Earnings

                              by Zacks Equity Research

                              PerkinElmer's (PKI) divestiture of the Medical Imaging segment in the last quarter is expected to impact earnings this season.

                                Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

                                by Zacks Equity Research

                                Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

                                  AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?

                                  by Zacks Equity Research

                                  The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter

                                    Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?

                                    by Zacks Equity Research

                                    CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.

                                      Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?

                                      by Zacks Equity Research

                                      Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.

                                        Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?

                                        by Zacks Equity Research

                                        Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.

                                          Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?

                                          by Zacks Equity Research

                                          Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                            What's in Store for Cardinal Health (CAH) in Q1 Earnings?

                                            by Zacks Equity Research

                                            Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.

                                              Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines

                                              by Zacks Equity Research

                                              Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.

                                                Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?

                                                by Zacks Equity Research

                                                Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.

                                                  Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?

                                                  by Zacks Equity Research

                                                  In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.